Crispr/Cas9-Based Model of Heterozygous CXCR4WT/R334x Mutation to Study Cellular Phenotypes in WHIM Syndrome


X4 Pharmaceuticals does not review or control the content on the website to which this hyperlink connects and this hyperlink does not constitute an endorsement by X4 Pharmaceuticals of the content of any non-X4 Pharmaceuticals website.